tagraxofusp-erzs (elzonris) Report issue

Biologics Recombinant protein ADC Orphan Drug FDA Approved FDA
AACT Drugs@FDA

Active Ingredient History

NOW
  • Now
Tagraxofusp, sold under the brand name Elzonris, is an anti-cancer medication for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN).   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: No
  • Payload: diphtheria toxin
  • Black Box: Missing data
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: Missing data

Drug Pricing (per unit)

United States

$18319.8800
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

sl-401 | tagraxofusp-erzs

Organizations (12)

Research & Development (12)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (11)

Approved Indications (1)


 

Dendritic Cell Sarcoma, Follicular (approved 2018)

Experimental Indications - Clinical Trial Phases 1-4 (10)


 

Leukemia-Lymphoma, Adult T-Cell (Phase 1/Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Leukemia, Myelomonocytic, Chronic (Phase 1/Phase 2)

Lymphoma, Large-Cell, Immunoblastic (Phase 1/Phase 2)

Multiple Myeloma (Phase 1/Phase 2)

Myelodysplastic Syndromes (Phase 1)

Myeloproliferative Disorders (Phase 1/Phase 2)

Plasmacytoma (Phase 2)

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (Phase 1/Phase 2)

Primary Myelofibrosis (Phase 1/Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 13
  • # of Trial Organizations: 12

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue